Everolimus for the treatment of pancreatic neuroendocrine tumors (Q38032923)

27 August 2017

Everolimus for the treatment of pancreatic neuroendocrine tumors (English)

1 reference

27 August 2017

Georg Feldmann

1

1 reference

27 August 2017

Savita Bisht

2

1 reference

27 August 2017

Ute Schütte

3

1 reference

27 August 2017

Jens Haarmann

4

1 reference

27 August 2017

Peter Brossart

5

1 reference

27 August 2017

language of work or name

English

0 references

publication date

8 August 2012

1 reference

Expert Opinion on Pharmacotherapy

27 August 2017

1 reference

27 August 2017

13

1 reference

27 August 2017

14

1 reference

27 August 2017

2073-2084

1 reference

Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors

27 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Surgical treatment of gastrointestinal neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

[Neuroendocrine tumors of the duodenum and pancreas. Surgical strategy].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Targeted modulation of MGMT: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Dramatic efficacy of chemotherapy with 5-fluorouracil and dacarbazine in a patient with metastatic glucagonoma and cardiac insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda) monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Pasireotide for the treatment of Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Positional cloning of the gene for multiple endocrine neoplasia-type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Characterization of mutations in patients with multiple endocrine neoplasia type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Menin, histone h3 methyltransferases, and regulation of cell proliferation: current knowledge and perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

EUS Detection of Pancreatic Endocrine Tumors in Asymptomatic Patients with Type 1 Multiple Endocrine Neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Distinct factors control histone variant H3.3 localization at specific genomic regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Altered telomeres in tumors with ATRX and DAXX mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

The Akt-mTOR tango and its relevance to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Rapamycin passes the torch: a new generation of mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

The mTOR signalling pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

PI3K and mTOR signaling pathways in cancer: new data on targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Estimating the cost of new drug development: is it really 802 million dollars?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Chemical modification of rapamycin: the discovery of SDZ RAD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Clinical pharmacokinetics of everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Effect of rifampin on apparent clearance of everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

COMPARISON OF METABOLIC ABNORMALITIES IN DIABETES MELLITUS INDUCED BY STREPTOZOTOCIN OR BY ALLOXAN

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Molecular pathology of the MEN1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

New Epigenetic Drivers of Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.713348

10.1517/14656566.2012.713348

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference